CClinicalTrials.gg
CompletedNCT01909973Medlink RCTUpdated Oct 8, 2019Results posted

Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment

An interventional study of MedLink System in Depression, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-08.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this project is to develop and pilot a mobile smartphone delivered intervention that will improve antidepressant medication care by providing medication adherence monitoring and support to the patient, feedback on patient adherence and response to treatment to the primary care team, and information to both patients and providers on guideline-congruent care personalized to the patient's response to antidepressant medication.

Read the detailed description

Major depressive disorder (MDD) is common and imposes a very high societal burden in terms of cost, morbidity, suffering, and mortality. While primary care is the de facto site for treatment of MDD, outcomes in primary care are poor. Two principal reasons for the poor outcomes in primary care are poor patient adherence to antidepressant medications (ADMs) and the failure of physicians to provide guideline-congruent care. This problem is aggravated by a lack of communication between patients and the care team.

A growing body of research indicates that primary care-centered strategies aimed at enhancing guideline-congruent care have not been effective. Interventions aimed at improving adherence in the patient have been successful in changing patient adherence behavior; however these frequently fail to improve depression outcomes, particularly when there is no intervention on the physician side to encourage optimization of ADMs. Recent developments in information and communications technologies (ICT) have opened new opportunities to improve health and mental health care, and to link patients and their providers. This study harnesses these advances to develop and pilot a system where ADM adherence will be passively measured using an electronic pill dispenser. The dispenser is connected to a mobile smartphone via Global System for Mobile Communications (GSM), so that targeted, timely reminders can be provided when the patient fails to take the ADM. When the patient is adherent, the patient will not be bothered with reminders. Depressive symptoms and side-effects will be periodically monitored weekly via the phone. Every 4 weeks, or if indicated (e.g intolerable side effects or urgent situations), primary care teams will receive notifications via the electronic medical record that include a summary of patient data on treatment response and side effects, guideline-congruent treatment recommendations based on patient data and a recommendation to contact the patient, if indicated. Simultaneously, a similar message will be provided to the patient via short message service (or text), including feedback, possible treatment options, and a recommendation to contact the physician's office. Thus, both the patient and care team will be activated to provide, request and adhere to guideline-congruent care.

The aim of this study is to develop and pilot the medLink system. Development will employ an iterative user-centered approach. The pilot trial will compare 12 weeks of the medLink system to a treatment as usual control among primary care patients with MDD initiating ADM treatment. Outcomes will include patient adherence to ADM, physician adherence to treatment guidelines, and depression.

02

Conditions studied

  • Depression

Browse trials for

Keywords

  • Depression
  • Antidepressant Medication
  • Adherence
  • Mobile Smartphone Intervention
  • Telemedicine
  • Primary Care
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 15 is below the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Has been prescribed an antidepressant medication by a Primary Care Provider, but has not yet initiated treatment
  • Has depression determined by primary care physician
  • Is familiar with the use of mobile phones
  • Is able and willing to carry the mobile phone
  • Is able to speak and read English
  • Is at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Is current taking an antidepressant medication or has taken one in the previous 3 months
  • Has visual, hearing, voice, or motor impairment that would prevent completion of study procedures or use of mobile phone
  • Is diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance dependence, or other diagnosis for which participation in this trial is either inappropriate or dangerous. Patients with substance dependence diagnoses who have been clean and sober for 12 months will be admitted if otherwise eligible
  • Is severely suicidal (has ideation, plan, and intent)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MedLink System

    For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.

    Behavioral: MedLink System

  • No intervention
    Treatment As Usual

    Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.

Interventions

  • BehavioralMedLink System

    Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient. The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.

06

What researchers measure

Primary outcomes

  1. Adherence to Antidepressant Medication

    Frequency of medication usage from baseline to end of treatment

    Time frame: Baseline, Week 4, Week 8, Week 12

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 measures degree of depression severity. Possible range of scores for the PHQ-9 is 0-27. Higher values represent a worse outcome. Specifically, scores of 0-4 indicate minimal or no depression; 5-9 is mild; 10-14 is moderate; 15-19 is moderately severe; and 20-27 is severe.

    Time frame: Baseline, Week 4, Week 8, Week 12

07

Results

Posted Oct 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneMedLink SystemTreatment As Usual
Started87
Completed77
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryAdherence to Antidepressant Medication

Frequency of medication usage from baseline to end of treatment

Time frame:
Baseline, Week 4, Week 8, Week 12
Reported as:
Count of participants · Participants
Adherence to Antidepressant Medication
ParticipantsMedLink SystemTreatment As Usual
Baseline — 01. Missed med in last 2 wks? - missed all 14 days00
Baseline — 01. Missed med in last 2 wks? - missed 6 to 8 days01
Baseline — 01. Missed med in last 2 wks? - missed 3 to 5 days01
Baseline — 01. Missed med in last 2 wks? - missed once/twice21
Baseline — 01. Missed med in last 2 wks? - No, took every day64
Baseline — 02a. Stopped med during last 2 wks? - Yes00
Baseline — 02a. Stopped med during last 2 wks? - No87
Baseline — 2aii. Stopped meds due to: Side effects - YesNANA
Baseline — 2aii. Stopped meds due to: Symptoms increase -YesNANA
Baseline — 2aii. Stopped meds due to: Symptoms decrease -YesNANA
Baseline — 2aii. Stopped meds due to: Ran out of meds -YesNANA
Baseline — 2aii. Stopped meds due to: Forgot to take -YesNANA
Baseline — 02b. Skipped med in last 2 wks? - Yes10
Baseline — 02b. Skipped med in last 2 wks? - No77
Baseline — 02bi. Skipped meds due to: Side effects - Yes0NA
Baseline — 02bi. Skipped meds due to: Symptoms increase -Yes0NA
Baseline — 02bi. Skipped meds due to: Symptoms decrease -Yes0NA
Baseline — 02bi. Skipped meds due to: Ran out of meds -Yes0NA
Baseline — 02bi. Skipped meds due to: Forgot to take -Yes1NA
Baseline — 02bi. Skipped meds due to: Other reason -Yes0NA
Baseline — 02c. Have you reduced med dosage? - Yes00
Baseline — 02c. Have you reduced med dosage? - No87
Baseline — 02ci. Reduced meds due to: Side effects - YesNANA
Baseline — 02ci. Reduced meds due to: Symptoms increase -YesNANA
Baseline — 02ci. Reduced meds due to: Symptoms decrease -YesNANA
Baseline — 02ci. Reduced meds due to: Ran out of meds -YesNANA
Baseline — 02ci. Reduced meds due to: Forgot to take -YesNANA
Baseline — 02ci. Reduced meds due to: Other reason -YesNANA
Baseline — 02d. Have you increased med dosage? - Yes11
Baseline — 02d. Have you increased med dosage? - No76
Baseline — 02di. Increased meds due to: Side effects - Yes00
Baseline — 02di.Increased meds due to: Symptoms increase -Yes00
Baseline — 02di.Increased meds due to: Symptoms decrease -Yes00
Baseline — 02di.Increased meds due to: Ran out of meds -Yes00
Baseline — 02di.Increased meds due to: Forgot to take -Yes00
Baseline — 02di.Increased meds due to: Other reason -Yes11
Baseline — 02ai. Stopped meds 3 days agoNANA
Baseline — 02ai. Stopped meds 14 days agoNANA
Baseline — 02ai. Stopped meds 2 ± 0 days days agoNANA
Week 4 — 01. Missed med in last 2 wks? - missed all 14 days00
Week 4 — 01. Missed med in last 2 wks? - missed 6 to 8 days01
Week 4 — 01. Missed med in last 2 wks? - missed 3 to 5 days00
Week 4 — 01. Missed med in last 2 wks? - missed once/twice14
Week 4 — 01. Missed med in last 2 wks? - No, took every day62
Week 4 — 02a. Stopped med during last 2 wks? - Yes01
Week 4 — 02a. Stopped med during last 2 wks? - No76
Week 4 — 2aii. Stopped meds due to: Side effects - YesNA0
Week 4 — 2aii. Stopped meds due to: Symptoms increase -YesNA1
Week 4 — 2aii. Stopped meds due to: Symptoms decrease -YesNA0
Week 4 — 2aii. Stopped meds due to: Ran out of meds -YesNA0
Week 4 — 2aii. Stopped meds due to: Forgot to take -YesNA1
Week 4 — 02b. Skipped med in last 2 wks? - Yes04
Week 4 — 02b. Skipped med in last 2 wks? - No73
Week 4 — 02bi. Skipped meds due to: Side effects - YesNA1
Week 4 — 02bi. Skipped meds due to: Symptoms increase -YesNA0
Week 4 — 02bi. Skipped meds due to: Symptoms decrease -YesNA0
Week 4 — 02bi. Skipped meds due to: Ran out of meds -YesNA1
Week 4 — 02bi. Skipped meds due to: Forgot to take -YesNA3
Week 4 — 02bi. Skipped meds due to: Other reason -YesNA0
Week 4 — 02c. Have you reduced med dosage? - Yes00
Week 4 — 02c. Have you reduced med dosage? - No77
Week 4 — 02ci. Reduced meds due to: Side effects - YesNANA
Week 4 — 02ci. Reduced meds due to: Symptoms increase -YesNANA
Week 4 — 02ci. Reduced meds due to: Symptoms decrease -YesNANA
Week 4 — 02ci. Reduced meds due to: Ran out of meds -YesNANA
Week 4 — 02ci. Reduced meds due to: Forgot to take -YesNANA
Week 4 — 02ci. Reduced meds due to: Other reason -YesNANA
Week 4 — 02d. Have you increased med dosage? - Yes12
Week 4 — 02d. Have you increased med dosage? - No65
Week 4 — 02di. Increased meds due to: Side effects - Yes00
Week 4 — 02di.Increased meds due to: Symptoms increase -Yes10
Week 4 — 02di.Increased meds due to: Symptoms decrease -Yes00
Week 4 — 02di.Increased meds due to: Ran out of meds -Yes00
Week 4 — 02di.Increased meds due to: Forgot to take -Yes00
Week 4 — 02di.Increased meds due to: Other reason -Yes02
Week 4 — 02ai. Stopped meds 3 days agoNA1
Week 4 — 02ai. Stopped meds 14 days agoNA0
Week 4 — 02ai. Stopped meds 2 ± 0 days days agoNA0
Week 8 — 01. Missed med in last 2 wks? - missed all 14 days01
Week 8 — 01. Missed med in last 2 wks? - missed 6 to 8 days00
Week 8 — 01. Missed med in last 2 wks? - missed 3 to 5 days11
Week 8 — 01. Missed med in last 2 wks? - missed once/twice03
Week 8 — 01. Missed med in last 2 wks? - No, took every day42
Week 8 — 02a. Stopped med during last 2 wks? - Yes01
Week 8 — 02a. Stopped med during last 2 wks? - No56
Week 8 — 2aii. Stopped meds due to: Side effects - YesNA0
Week 8 — 2aii. Stopped meds due to: Symptoms increase -YesNA0
Week 8 — 2aii. Stopped meds due to: Symptoms decrease -YesNA1
Week 8 — 2aii. Stopped meds due to: Ran out of meds -YesNA0
Week 8 — 2aii. Stopped meds due to: Forgot to take -YesNA0
Week 8 — 02b. Skipped med in last 2 wks? - Yes13
Week 8 — 02b. Skipped med in last 2 wks? - No44
Week 8 — 02bi. Skipped meds due to: Side effects - Yes00
Week 8 — 02bi. Skipped meds due to: Symptoms increase -Yes00
Week 8 — 02bi. Skipped meds due to: Symptoms decrease -Yes00
Week 8 — 02bi. Skipped meds due to: Ran out of meds -Yes01
Week 8 — 02bi. Skipped meds due to: Forgot to take -Yes02
Week 8 — 02bi. Skipped meds due to: Other reason -Yes10
Week 8 — 02c. Have you reduced med dosage? - Yes11
Week 8 — 02c. Have you reduced med dosage? - No46
Week 8 — 02ci. Reduced meds due to: Side effects - Yes00
Week 8 — 02ci. Reduced meds due to: Symptoms increase -Yes00
Week 8 — 02ci. Reduced meds due to: Symptoms decrease -Yes01
Week 8 — 02ci. Reduced meds due to: Ran out of meds -Yes00
Week 8 — 02ci. Reduced meds due to: Forgot to take -Yes00
Week 8 — 02ci. Reduced meds due to: Other reason -Yes10
Week 8 — 02d. Have you increased med dosage? - Yes00
Week 8 — 02d. Have you increased med dosage? - No57
Week 8 — 02di. Increased meds due to: Side effects - YesNANA
Week 8 — 02di.Increased meds due to: Symptoms increase -YesNANA
Week 8 — 02di.Increased meds due to: Symptoms decrease -YesNANA
Week 8 — 02di.Increased meds due to: Ran out of meds -YesNANA
Week 8 — 02di.Increased meds due to: Forgot to take -YesNANA
Week 8 — 02di.Increased meds due to: Other reason -YesNANA
Week 8 — 02ai. Stopped meds 3 days agoNA0
Week 8 — 02ai. Stopped meds 14 days agoNA1
Week 8 — 02ai. Stopped meds 2 ± 0 days days agoNA0
Week 12 — 01. Missed med in last 2 wks? - missed all 14 days01
Week 12 — 01. Missed med in last 2 wks? - missed 6 to 8 days10
Week 12 — 01. Missed med in last 2 wks? - missed 3 to 5 days01
Week 12 — 01. Missed med in last 2 wks? - missed once/twice13
Week 12 — 01. Missed med in last 2 wks? - No, took every day32
Week 12 — 02a. Stopped med during last 2 wks? - Yes02
Week 12 — 02a. Stopped med during last 2 wks? - No55
Week 12 — 2aii. Stopped meds due to: Side effects - YesNA0
Week 12 — 2aii. Stopped meds due to: Symptoms increase -YesNA0
Week 12 — 2aii. Stopped meds due to: Symptoms decrease -YesNA1
Week 12 — 2aii. Stopped meds due to: Ran out of meds -YesNA1
Week 12 — 2aii. Stopped meds due to: Forgot to take -YesNA0
Week 12 — 02b. Skipped med in last 2 wks? - Yes12
Week 12 — 02b. Skipped med in last 2 wks? - No45
Week 12 — 02bi. Skipped meds due to: Side effects - Yes00
Week 12 — 02bi. Skipped meds due to: Symptoms increase -Yes00
Week 12 — 02bi. Skipped meds due to: Symptoms decrease -Yes00
Week 12 — 02bi. Skipped meds due to: Ran out of meds -Yes01
Week 12 — 02bi. Skipped meds due to: Forgot to take -Yes11
Week 12 — 02bi. Skipped meds due to: Other reason -Yes00
Week 12 — 02c. Have you reduced med dosage? - Yes10
Week 12 — 02c. Have you reduced med dosage? - No47
Week 12 — 02ci. Reduced meds due to: Side effects - Yes0NA
Week 12 — 02ci. Reduced meds due to: Symptoms increase -Yes0NA
Week 12 — 02ci. Reduced meds due to: Symptoms decrease -Yes1NA
Week 12 — 02ci. Reduced meds due to: Ran out of meds -Yes0NA
Week 12 — 02ci. Reduced meds due to: Forgot to take -Yes0NA
Week 12 — 02ci. Reduced meds due to: Other reason -Yes0NA
Week 12 — 02d. Have you increased med dosage? - Yes00
Week 12 — 02d. Have you increased med dosage? - No57
Week 12 — 02di. Increased meds due to: Side effects - YesNANA
Week 12 — 02di.Increased meds due to: Symptoms increase -YesNANA
Week 12 — 02di.Increased meds due to: Symptoms decrease -YesNANA
Week 12 — 02di.Increased meds due to: Ran out of meds -YesNANA
Week 12 — 02di.Increased meds due to: Forgot to take -YesNANA
Week 12 — 02di.Increased meds due to: Other reason -YesNANA
Week 12 — 02ai. Stopped meds 3 days agoNA0
Week 12 — 02ai. Stopped meds 14 days agoNA0
Week 12 — 02ai. Stopped meds 2 ± 0 days days agoNA2
SecondaryPatient Health Questionnaire-9 (PHQ-9)

The PHQ-9 measures degree of depression severity. Possible range of scores for the PHQ-9 is 0-27. Higher values represent a worse outcome. Specifically, scores of 0-4 indicate minimal or no depression; 5-9 is mild; 10-14 is moderate; 15-19 is moderately severe; and 20-27 is severe.

Time frame:
Baseline, Week 4, Week 8, Week 12
Reported as:
Mean · units on a scale
Patient Health Questionnaire-9 (PHQ-9)
units on a scaleMedLink SystemTreatment As Usual
Baseline15.25 ± 6.0711.43 ± 2.15
Week 410.57 ± 8.645.57 ± 2.94
Week 85.80 ± 4.553.43 ± 2.51
Week 125.20 ± 2.392.00 ± 2.24

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MedLink System0/8 (0%)0/8 (0%)0/8 (0%)
Treatment As Usual0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)MedLink SystemTreatment As UsualTotal
Mean49.3 ± 17.0442.3 ± 14.0246 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)MedLink SystemTreatment As UsualTotal
Female4711
Male404
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MedLink SystemTreatment As UsualTotal
Hispanic or Latino011
Not Hispanic or Latino8614
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MedLink SystemTreatment As UsualTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American538
White347
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Northwestern University, Northwestern Medicine
    Chicago, Illinois 60611, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01909973
Lead sponsor
Northwestern University
Responsible party
David Mohr (Director, Center for Behavioral Intervention Technologies; Professor, Department of Preventive Medicine, Northwestern University) — Principal investigator
First posted
Jul 29, 2013
Start date
Apr 2012
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Oct 8, 2019
Last update
Oct 8, 2019

Study contacts

David C Mohr, Ph.D.
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion